Tumor burden and growth kinetics, tumor microenvironment, cell death inhibition, and EMT contribute to therapeutic resistance (229), which can be leveraged by targeting FBXW7 to elevate therapeutic sensitivity and the prognosis of patients. This evidence concerns the gene FBXW7 and neoplasm.